These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

558 related articles for article (PubMed ID: 22487082)

  • 1. Antimalarial drugs and drug targets specific to fatty acid metabolic pathway of Plasmodium falciparum.
    Qidwai T; Khan F
    Chem Biol Drug Des; 2012 Aug; 80(2):155-72. PubMed ID: 22487082
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Plasmodium falciparum: new molecular targets with potential for antimalarial drug development.
    Gardiner DL; Skinner-Adams TS; Brown CL; Andrews KT; Stack CM; McCarthy JS; Dalton JP; Trenholme KR
    Expert Rev Anti Infect Ther; 2009 Nov; 7(9):1087-98. PubMed ID: 19883329
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Helicases - feasible antimalarial drug target for Plasmodium falciparum.
    Tuteja R
    FEBS J; 2007 Sep; 274(18):4699-704. PubMed ID: 17824956
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tropical infectious diseases: metabolic maps and functions of the Plasmodium falciparum apicoplast.
    Ralph SA; van Dooren GG; Waller RF; Crawford MJ; Fraunholz MJ; Foth BJ; Tonkin CJ; Roos DS; McFadden GI
    Nat Rev Microbiol; 2004 Mar; 2(3):203-16. PubMed ID: 15083156
    [No Abstract]   [Full Text] [Related]  

  • 5. [Transport proteins as drug targets in Plasmodium falciparum. New perspectives in the treatment of malaria].
    Ellekvist P; Colding H
    Ugeskr Laeger; 2006 Mar; 168(13):1314-7. PubMed ID: 16579884
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antimalarial drug targets and drugs targeting dolichol metabolic pathway of Plasmodium falciparum.
    Qidwai T; Priya A; Khan NA; Tripathi H; Khan F; Darokar MP; Pal A; Bawankule DU; Shukla RK; Bhakuni RS
    Curr Drug Targets; 2014 Apr; 15(4):374-409. PubMed ID: 23848395
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The apicoplast as an antimalarial drug target.
    Ralph SA; D'Ombrain MC; McFadden GI
    Drug Resist Updat; 2001 Jun; 4(3):145-51. PubMed ID: 11768328
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Plasmodium kinases as targets for new-generation antimalarials.
    Lucet IS; Tobin A; Drewry D; Wilks AF; Doerig C
    Future Med Chem; 2012 Dec; 4(18):2295-310. PubMed ID: 23234552
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Is PfCRT a channel or a carrier? Two competing models explaining chloroquine resistance in Plasmodium falciparum.
    Sanchez CP; Stein WD; Lanzer M
    Trends Parasitol; 2007 Jul; 23(7):332-9. PubMed ID: 17493873
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Mechanism of action of antimalarials. Value of combined atovaquone/proguanil].
    Touze JE; Fourcade L; Pradines B; Hovette P; Paule P; Heno P
    Med Trop (Mars); 2002; 62(3):219-24. PubMed ID: 12244914
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evolutionary paradigm of chloroquine-resistant malaria in India.
    Das A; Dash AP
    Trends Parasitol; 2007 Apr; 23(4):132-5. PubMed ID: 17280870
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Estimating novel potential drug targets of Plasmodium falciparum by analysing the metabolic network of knock-out strains in silico.
    Fatumo S; Plaimas K; Mallm JP; Schramm G; Adebiyi E; Oswald M; Eils R; König R
    Infect Genet Evol; 2009 May; 9(3):351-8. PubMed ID: 18313365
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synthesis, antimalarial evaluation and molecular modeling studies of hydroxyethylpiperazines, potential aspartyl protease inhibitors, part 2.
    Cunico W; Gomes CR; Facchinetti V; Moreth M; Penido C; Henriques MG; Varotti FP; Krettli LG; Krettli AU; da Silva FS; Caffarena ER; de Magalhães CS
    Eur J Med Chem; 2009 Sep; 44(9):3816-20. PubMed ID: 19403210
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antimalarial drugs inhibiting hemozoin (beta-hematin) formation: a mechanistic update.
    Kumar S; Guha M; Choubey V; Maity P; Bandyopadhyay U
    Life Sci; 2007 Feb; 80(9):813-28. PubMed ID: 17157328
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Relict plastidic metabolic process as a potential therapeutic target.
    Sharma D; Soni R; Rai P; Sharma B; Bhatt TK
    Drug Discov Today; 2018 Jan; 23(1):134-140. PubMed ID: 28987288
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Metabolic enzymes as potential drug targets in Plasmodium falciparum.
    Subbayya IN; Ray SS; Balaram P; Balaram H
    Indian J Med Res; 1997 Aug; 106():79-94. PubMed ID: 9291679
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibitors of nonhousekeeping functions of the apicoplast defy delayed death in Plasmodium falciparum.
    Ramya TN; Mishra S; Karmodiya K; Surolia N; Surolia A
    Antimicrob Agents Chemother; 2007 Jan; 51(1):307-16. PubMed ID: 17060533
    [TBL] [Abstract][Full Text] [Related]  

  • 18. pfcrt is more than the Plasmodium falciparum chloroquine resistance gene: a functional and evolutionary perspective.
    Cooper RA; Hartwig CL; Ferdig MT
    Acta Trop; 2005 Jun; 94(3):170-80. PubMed ID: 15866507
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In silico multiple-targets identification for heme detoxification in the human malaria parasite Plasmodium falciparum.
    Phaiphinit S; Pattaradilokrat S; Lursinsap C; Plaimas K
    Infect Genet Evol; 2016 Jan; 37():237-44. PubMed ID: 26626103
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A proteomic glimpse into the effect of antimalarial drugs on Plasmodium falciparum proteome towards highlighting possible therapeutic targets.
    Dousti M; Manzano-Román R; Rashidi S; Barzegar G; Ahmadpour NB; Mohammadi A; Hatam G
    Pathog Dis; 2021 Jan; 79(1):. PubMed ID: 33202000
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.